Role of efaproxiral in metastatic brain tumors

Expert Review of Anticancer Therapy

Volumn 6, Issue 4, 2006, Pages 477-485

  Engel, Ryan H ^a   Kaklamani, Virginia G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Allosteric modifier; Brain metastases; Deoxynucleic acid; Efaproxiral; Motexafin gadolinium; Oxygen hemoglobin dissociation curve; Radiosensitizer; Reactive oxygen species; RSR13; Whole brain radiation therapy

Indexed keywords

CARMUSTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFAPROXIRAL; EFAPROXYN; GADOLINIUM TEXAPHYRIN; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; VANCOMYCIN; ANILINE DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANEMIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPOXIA; CLINICAL TRIAL; CYTOTOXICITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; ERYTHROCYTE; EVIDENCE BASED MEDICINE; FREQUENCY ANALYSIS; HEADACHE; HUMAN; HYPOTENSION; HYPOVOLEMIA; HYPOXEMIA; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; NAUSEA; OVERALL SURVIVAL; OXYGEN THERAPY; OXYGENATION; PRACTICE GUIDELINE; QUALITY OF LIFE; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TISSUE OXYGENATION; TUMOR CELL; VOMITING; ANIMAL; BRAIN TUMOR; BREAST TUMOR; METASTASIS; PATHOLOGY; REVIEW;

ANILINE COMPOUNDS; ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; HUMANS; PROPIONIC ACIDS;

EID: 33746275903     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.4.477     Document Type: Article

References (61)

1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J. Neurooncol. 75(1), 5-14 (2005).
2. Posner JB. Management of brain metastases. Rev. Neurol. 148(6-7), 477-487 (1992).
3. Zimm S, Wampler GL, Stablein D et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2), 384-394 (1981).
4. Tsukada Y, Fouad A, Pickren JW et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52(12), 2349-2354 (1983).
5. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35(2), 219-226 (1985).
6. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann. Neurol. 7(6), 529-541 (1980).
7. Schouten LJ, Rutten J, Huveneers HA et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10), 2698-2705 (2002).
8. Coia LR. The role of radiation therapy in the treatment of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 23(1), 229-238 (1992).
9. DiStefano A, Yong Yap Y, Hortobagyi GN et al. The natural history of breast cancer patients with brain metastases. Cancer 44(5), 1913-1918 (1979).
10. Borgelt B, Gelber R, Kramer S et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 6(1), 1-9 (1980).
11. Fokstuen T, Wilking N, Rutqvist LE et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res. Treat. 62(3), 211-216 (2000).
12. Ewend MG, Carey LA, Morris DE et al. Brain metastases. Curr. Treat. Options Oncol. 2(6), 537-547 (2001).
13. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J. Clin. Oncol. 22(17), 3608-3617 (2004).
14. Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 20(17), 3644-3650 (2002).
15. Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest. 8(3-4), 327-334 (1990).
16. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599-1605 (1999).
17. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58(4), 832-839 (1986).
18. Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J. Neurooncol. 24(3), 299-301 (1995).
19. Kondziolka D, Patel A, Lunsford LD et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 45(2), 427-434 (1999).
20. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 745-751 (1997).
21. Mehta MP, Khuntia D. Current strategies in whole-brain radiation therapy for brain metastases. Neurosurgery 57(5 Suppl.), S33-S44 (2005).
22. Abelhoff M, Armitage J, Lichter A. Radiation Therapy. In: Clinical Oncology. Strauss. M (Ed.). Churchill Livingston, Philadelphia, PA, USA, 423-450 (2000).
23. Shaw E, Scott C, Suh J et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 21(12), 2364-2371 (2003).
24. Hall E. The oxygen effects and reoxygenation. In: Radiobiology for the Radiologist. JB Lippincott, PA, USA, 137-155 (1988).
25. 2 tension measurements. Cancer Res. 51(12), 3316-3322 (1991).
26. Brizel DM, Sibley GS, Prosnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38(2), 285-289 (1997).
27. del Regato JA. Milestones in therapeutic radiology. Front. Radiat. Ther. Oncol. 25 4-9 (1991).
28. Eyre HJ, Ohlsen JD, Frank J et al. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J. Neurooncol. 2(4), 325-330 (1984).
29. Komarnicky LT, Phillips TL, Martz K et al. A randomized Phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 20(1), 53-58 (1991).
30. Prados MD, Scott CB, Rotman M et al. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 40(3), 653-659 (1998).
31. Abraham DJ, Perutz MF, Phillips SE. Physiological and x-ray studies of potential antisickling agents. Proc. Natl Acad. Sci. USA 80(2), 324-328 (1983).
32. Abraham DJ, Wireko FC, Randad RS et al. Allosteric modifiers of hemoglobin: 2-[4- (3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2- methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 31(38), 9141-9149 (1992).
33. Perutz MF, Poyart C. Bezafibrate lowers oxygen affinity of haemoglobin. Lancet 2(8355), 881-882 (1983).
34. Grella M, Danso-Danquah R, Safo Mk et al. Synthesis and structure-activity relationships of chiral allosteric modifiers of hemoglobin. J. Med. Chem. 43(25), 4726-4737 (2000).
35. Moody E, John R. Therapeutic gases: oxygen, carbon dioxide, nitric oxide & helium. In: Goodman & Gilman's the Pharmacological Basis of Therapeutics. Hardman J, LL, Gilman AG (Eds). McGraw-Hill, OH, USA, 385-398 (2001).
36. Ganong. Gas transport between the lungs and tissues. In: Review of Medical Physiology. McGraw-Hill Company, OH, USA, 666-671 (2005).
37. Safo MK, Moure CM, Burnett JC et al. High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci. 10(5), 951-957 (2001).
38. 2) with or without RSR13 (efaproxiral) in patients with brain metastases: results of a randomized REACH (RT-009) study. Am. Soc. Clin. Oncol. Annual Meeting Proceedings. LA, USA, 1534 (2004).
39. Kolman A. Efaproxiral (Allos Therapeutics). IDrugs 6(8), 795-801 (2003).
40. Wireko FC, Kellogg GE, Abraham DJ. Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/ interaction analysis of novel hemoglobin oxygen effectors. J. Med. Chem. 34(2), 758-767 (1991).
41. Khandelwal SR, Randad RS, Lin PS et al. Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am. J. Physiol. 265(4 Pt 2), H1450-1453 (1993).
42. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK et al. A Phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int. J. Radiat. Oncol. Biol. Phys. 49(4), 1133-1139 (2001).
43. Rockwell S, Kelley M. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice. Radiat. Oncol. Investig. 6(5), 199-208 (1998).
44. Teicher BA, Wong JS, Takeuchi H et al. Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo. Cancer Chemother. Pharmacol. 42(1), 24-30 (1998).
45. Wahr JA, Gerber M, Venitz J et al. Allosteric modification of oxygen delivery by hemoglobin. Anesth. Analg. 92(3), 615-620 (2001).
46. Kleinberg L, Grossman SA, Piantadosi S et al. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 17(8), 2593-2603 (1999).
47. Suh JH, Stea B, Nabid A et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 24(1), 106-114 (2006).
48. Grinberg OY, Miyake M, Hou H et al. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats. Adv. Exp. Med. Biol. 530 287-296 (2003).
49. Gaspar LE, Scott C, Murray K et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47(4), 1001-1006 (2000).
50. Stea B, Suh J, Shaw E et al. Efaproxiral (Efaproxyn™) as an adjunct to whole brain radiation for the treatment of brain metastases originating from breast cancer: updated survival results of the randomized REACH (RT-009) study. San Antonio Breast Conf. Symposium. San Antonio, TX, USA, 4064 (2004).
51. Shaw E, Stea B, Pinter T et al. Pharmacokinetics (PK) of RSR13 (Efaproxiral) predict survival in patients with brain metastases randomized to receive whole brain radiation therapy (WBRT) with or without RSR13 (REACH RT-009). Am. Soc. Clin. Oncol. Annual Meeting Proceedings. LA, USA, 1561 (2004).
52. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13. Drugs R D 6(3), 178-185 (2005).
53. National Cancer Institute. Advisory committee recommends against approval of two new cancer drugs. NCI Cancer Bulletin. 1(19), 1-2 (2004).
54. Stea B, Nabid A, Kresl J et al. Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy. Am. Soc. Clin. Oncol. Annual Meeting Proceedings. LA, USA, 3090 (2004).
55. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363(9422), 1665-1672 (2004).
56. Choy H, Nabid A, Stea B et al. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5918-5928 (2005).
57. New PZ, Grossman T, Mikkelsen T et al. Evaluation of safety and tolerance of esclating doses of RSR13 administered with a fixed dose of BCNU every six weeks in patients with recurrent malignat glioma: results of the Phase I NABTT 98066 clinical trial. Am. Soc. Clin. Oncol. Annual Meeting Proceedings. LA, USA, 1533 (2004).
58. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat. Rev. 31(4), 312-318 (2005).
59. Suh JH. Efaproxiral: a novel radiation sensitiser. Expert Opin. Investig. Drugs 13(5), 543-550 (2004).
60. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
61. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann. Oncol. 16(11), 1772-1777 (2005).